Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Ono Pharmaceutical has entered into an agreement to develop and commercialize KAI Pharmaceuticals' lead product candidate KAI-4169 in Japan.
Subscribe to our email newsletter
KAI-4169, an intravenous (IV) formulation used in the treatment of secondary hyperparathyroidism (SHPT) in patients with chronic kidney disease-mineral and bone disorder (CKD-MBD), is in Phase 2 clinical testing.
As per the agreement, Ono receives rights to all indications for injectable formulations of KAI-4169 in Japan and also retains marketing rights in all other regions.
KAI will receive $13m as an upfront payment from Ono and will also receive a royalty on sales.
KAI Pharmaceuticals president and CEO Steven James said they are excited about the continued momentum of the KAI-4169 program, and they anticipate completing the Phase 2 trial and reporting data by the end of this year.